arrow
A

Alexandra S. Zimmer

national cancer institute
H指数:16
被引数:1,669

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors

循环肿瘤DNA细化新辅助治疗耐药乳腺肿瘤的危险分层

2025-12-090
OAAI
A Phase II Pilot Study of Anti-PD-L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple-Negative Breast Cancer With or Without Germline BRCA Mutation

一项关于抗PD-L1药物Durvalumab和PARP抑制剂Olaparib在携带或不携带胚系BRCA突变的转移性三阴性乳腺癌患者中的II期探索性研究

2025-12-080
OAAI
A CSF-1R inhibitor both prevents and treats triple-negative breast cancer brain metastases in hematogenous preclinical models

一种CSF-1R抑制剂在血液传播的预临床模型中既可预防又可治疗三阴性乳腺癌脑转移瘤

2025-08-040
OAAI
Consortium for Intracranial Metastasis Academic Research (CIMARa): Global interdisciplinary collaborations to improve outcomes of patient with brain metastases

脑转移瘤学术研究联盟(CIMARa):全球跨学科合作以改善脑转移瘤患者预后

2025-03-040
OA
Initial experience in implementing quantitative DCE-MRI to predict breast cancer therapy response in a multi-center and multi-vendor platform setting
2024-11-290
OAAI
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Datopotamab-deruxtecan治疗早期乳腺癌: 序贯多重分配随机I-SPY2.2 2期试验

2024-09-141
PRE
First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors (vol 42, 76, 2023)
2023-04-262
OAAI
First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors
2023-03-297
OAAI
Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline

脑转移瘤的放射治疗: ASTRO临床实践指南

2022-07-01182
OAAI
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
2020-08-14148
OAAI
A phase Ib trial of sequential combinations of BN-brachyury, entinostat, ado-trastuzumab emtansine (T-DM1) and bintrafusp alfa (M7824) in advanced stage breast cancer (BrEAsT)
2020-02-152
PRE
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses

PD-L1抑制剂durvalumab联合PARP抑制剂olaparib和VEGFR1-3抑制剂cedimanib在复发性女性癌症中的I期研究,具有生物标志物分析

2019-07-2594
OAAI